Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Consolidated Net Income: 2022-2025

Historic Consolidated Net Income for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to -$78.4 million.

  • Praxis Precision Medicines' Consolidated Net Income fell 37.87% to -$78.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$293.1 million, marking a year-over-year decrease of 78.71%. This contributed to the annual value of -$200.2 million for FY2024, which is 58.39% down from last year.
  • Latest data reveals that Praxis Precision Medicines reported Consolidated Net Income of -$78.4 million as of Q3 2025, which was down 3.01% from -$76.1 million recorded in Q2 2025.
  • Praxis Precision Medicines' Consolidated Net Income's 5-year high stood at -$25.5 million during Q3 2023, with a 5-year trough of -$78.4 million in Q3 2025.
  • Its 3-year average for Consolidated Net Income is -$50.5 million, with a median of -$41.9 million in 2024.
  • As far as peak fluctuations go, Praxis Precision Medicines' Consolidated Net Income skyrocketed by 44.67% in 2023, and later plummeted by 130.01% in 2024.
  • Quarterly analysis of 4 years shows Praxis Precision Medicines' Consolidated Net Income stood at -$41.5 million in 2022, then spiked by 32.92% to -$27.8 million in 2023, then plummeted by 130.01% to -$64.0 million in 2024, then slumped by 37.87% to -$78.4 million in 2025.
  • Its Consolidated Net Income was -$78.4 million in Q3 2025, compared to -$76.1 million in Q2 2025 and -$74.7 million in Q1 2025.